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Structure 2007, revised 8/17/07 
Phosphorylation-induced conformational switching of CPI-17 produces a 
potent myosin phosphatase inhibitor.   
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SUMMARY 
Phosphorylation of endogenous inhibitor proteins specific for type-1 Ser/Thr 
phosphatase (PP1) provides a mechanism for reciprocal coordination of kinase and 
phosphatase activities. Phosphorylation of Thr38 in the inhibitor protein CPI-17 
transduces G-protein-mediated signaling into a > 1000-fold increase of inhibitory 
potency toward myosin phosphatase. We show here the solution NMR structure of 
phospho-T38-CPI-17 with r. m. s. d. of 0.36 ± 0.06 Å for the backbone secondary 
structure, which reveals how phosphorylation triggers a conformational change and 
exposes the PP1 inhibitory surface.  This active conformation is stabilized by the 
formation of a hydrophobic core of intercalated side-chains, which is not formed in a 
phospho-mimetic D38 mutant form of CPI-17. Thus, the profound increase in potency 
of CPI-17 arises from phosphorylation, conformational change and hydrophobic 
stabilization of a rigid structure that poses the phosphorylated residue on the protein 
surface and restricts its hydrolysis by myosin phosphatase. Our results provide 
structural insights into transduction of kinase signals by PP1 inhibitor proteins. 
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INTRODUCTION 
Type-1 Ser/Thr phosphatase (PP1) is conserved among all eukaryotes and is 
responsible for regulation of a plethora of cellular functions,.  A specific multisubunit form 
of PP1, called myosin phosphatase, is a ubiquitous enzyme that functions in various 
signaling circuits (Hartshorne, et al, 2004). Myosin phosphatase is a trimeric holoenzyme 
consisting of a catalytic subunit of PP1 and a myosin targeting MYPT1 subunit with an 
accessory M21 subunit (Hartshorne, et al, 2004). The N-terminal ankyrin-repeat domain of 
MYPT1, including a PP1 binding site, functions as an allosteric regulator of the catalytic 
subunit.  On the other hand, C-terminal domain is phosphorylated by multiple kinases, 
ROCK, ZIPK and ILK, that is involved in the inhibition of myosin phosphatase in response 
to G-protein activation (Trinkle-Mulcahy, et al, 1995). In smooth muscle, agonist-induced 
activation of G-protein enhances the activity of Ca2+/calmodulin-dependent myosin 
light-chain kinase, and coincidently suppresses the activity of myosin phosphatase via the 
activation of kinases ROCK and PKC (Kitazawa, et al, 1991; Somlyo, et al, 2003).  The 
inhibition of myosin phosphatase is required for robust and sustained myosin 
phosphorylation in response to agonist stimuli (Dimopoulos, et al, 2007). The inhibition of 
myosin phosphatase is also involved in regulation of cytoskeletal reorganization during cell 
migration (Kawano, et al, 1999) and cytokinesis (Matsumura, 2005).   
In addition to direct phosphorylation of the MYPT1 subunit myosin phosphatase is 
regulated by a specific inhibitor protein, CPI-17, that is predominantly expressed in smooth 
muscles and neurons (Eto, et al, 1997; Eto, et al, 2002; Woodsome, et al, 2001). 
Phosphorylation of CPI-17 at Thr38 is necessary and sufficient to convert the protein into a 
potent inhibitor of myosin phosphatase (Eto, et al, 1995; Kitazawa, et al, 2000; Koyama, et al, 
2000; Pang, et al, 2005).  Other PP1 holoenzymes in cells are insensitive to 
phospho-CPI-17 (P-CPI-17) (Senba, et al, 1999).  One example is a glycogen-bound form 
of PP1 holoenzyme, which binds P-T38-CPI-17 but dephosphorylates it .  In contrast, with 
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myosin phosphatase there is binding of P-T38-CPI-17, but the hydrolysis step is arrested, 
resulting in formation of inactive complex.  Thus, P-T38-CPI-17 can be a substrate or an 
inhibitor of different forms of PP1, depending on regulatory subunits (Eto, et al, 2004). In 
smooth muscle cells, rapid phosphorylation of CPI-17 at Thr38 occurs in parallel to 
phosphorylation of myosin via activation of Ca2+-dependent PKC, followed by prolonged 
phosphorylation, maintained via RhoA/ROCK signal (Dimopoulos, et al, 2007). 
Phosphorylation of CPI-17 is reduced through a cGMP-dependent pathway in response to 
nitric oxide release, in parallel to muscle relaxation (Bonnevier, et al, 2004; Etter, et al, 2001). 
Thus, in smooth muscles phosphorylation of CPI-17 functions to inhibit myosin phosphatase 
and thereby promote myosin phosphorylation and contraction. 
 
Fluctuation in the expression and the phosphorylation levels of CPI-17 is associated 
with smooth muscle-related diseases, such as intestinal bowel disease (Ohama, et al, 2003), 
asthma (Sakai, et al, 2005), pulmonary hypertension (Dakshinamurti, et al, 2005), and 
diabetic dysfunction of smooth muscle (Chang, et al, 2006; Xie, et al, 2006). In Purkinje 
neurons, CPI-17 is essential to maintain G-protein-mediated AMPA receptor internalization 
and generate long-term synaptic depression in response to stimulation(Eto, et al, 2002). In 
addition, the upregulation of CPI-17 was found in tumor cells, which causes 
hyperphosphorylation of tumor suppressor merlin (NF2) and transformation of cells (Jin, et 
al, 2006). Therefore, CPI-17 poses a potential target of pharmaceutical approaches for these 
diseases.  
Determination of the three-dimensional (3D) structure of unphospho-CPI-17 by 
NMR revealed a 2x2 pairing of a four-helix bundle, forming a unique V-shape structure 
(Ohki, et al, 2001).   The phosphorylation site, Thr38, is located in a loop structure (P-loop) 
at the N-terminus, sitting in a cavity between helices (Ohki, et al, 2001). When Thr38 is 
substituted for Asp to mimic phosphorylation, the P-loop becomes exposed to solvent, 
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suggesting a conformational change of the P-loop upon activation of CPI-17 (Ohki, et al, 
2003).  However, structural analysis of the basis for enhanced inhibition of myosin 
phosphatase by CPI-17 was limited because the D38-form of CPI-17 is significantly less 
potent, compared with phospho (P)-T38-CPI-17 (Ohki, et al, 2003). We concluded that 
despite a conformational change in the D38 protein, this structure was not the same as that of 
the highly potent and fully activated P-T38-CPI-17.  Therefore we prepared CPI-17 protein 
fully phosphorylated with PKC and determined the 3D structure using multidimensional 
NMR techniques.  The 3D structure indicates a global conformational switch upon 
phosphorylation of CPI-17 at Thr38, shows differences relative to the phospho-mimetic D38 
structure and exposes novel interactions between P-CPI-17 and myosin phosphatase. 
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RESULTS  
Phosphorylation of CPI-17(22-120) 
The inhibitory domain of CPI-17 comprised of residues 22-120 is conserved among 
the CPI-17 family of PP1 inhibitor proteins, such as PHI-1, KEPI and GBPI (Figure 1A).  
The recombinant 13C/15N-labeled 22-120 protein was phosphorylated to completion by 
extended incubation with purified PKC (Supplementary Figure S1), and subjected to a series 
of multidimensional NMR experiments (Supplementary Figure S2, and S3). Figure 1B shows 
part of the 1H-15N HSQC spectrum of 13C/15N-labeled P-CPI-17 (red) superimposed on the 
previous spectra of unphosphorylated (gray) and Asp-substituted D38-CPI-17 (blue) 
(22-120) proteins (Ohki, et al, 2003). The backbone amide resonance of Thr38 is shifted to 
downfield upon phosphorylation (Figure 1B).  This phosphorylation-dependent downfield 
shift is consistent with a previous report on phosphorylation of the tau protein (Landrieu, et 
al, 2006) .  In addition, the phosphorylation at Thr38 induces a relatively large chemical 
shift change of amide resonances from the neighbor residues in the phosphorylation loop 
(P-loop), such as V39 and Y41.  The chemical shifts of these residues in P-T38-CPI-17 did 
not match those in the D38-form of CPI-17 (blue).  This suggests that the conformation of 
the phosphorylated protein differs from the conformation of the protein with a 
“phosphomimetic” mutation to introduce an Asp at the same residue. Overall the profiles of 
HSQC spectra in the full-scale chart (Supplementary Figure S2) are similar in all three forms 
of CPI-17 examined by NMR. Furthermore, there was no evidence of multiple conformation 
states in the spectrum of P-T38-CPI-17. 
 
Structure of phospho-T38-CPI-17 
The 3D structure of P- T38-CPI-17 was calculated using 1,518 structural restraints 
obtained from the NMR data (Supplementary Figure S3), summarized in Supplementary 
Table S1. Overall the topology of P-T38-CPI-17 is composed of a long loop with the 
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phosphorylation site, Thr38, followed by a left-handed 4-helix bundle (termed A to D from 
the N-terminus) (Figure 2). The four helices are arranged in an anti-parallel orientation. The 
structure of residues 22 to 31 at the N terminus of the truncated protein was in a flexible 
conformation, seen by lack of long-range NOE. This conclusion is supported by very small 
heteronuclear 15N-{1H} NOE values (Supplementary Figure S4) and the fast H-D exchange 
rates (data not shown) of these10 residues.  In contrast, the conserved region of residues 32 
to 40 with phospho-Thr38 (P-Thr38), termed the P-loop, converged into a single 
conformation with a backbone r.m.s.d. of 1.18 + 0.27 Å, with relatively higher heteronuclear 
15N-{1H} NOE values (Supplementary Figure S4, red). The P-Thr38 side chain is exposed to 
solvent, and the P-loop lays on the surface of the four-helix bundle. The side chains of Val37 
and Val39 face into the protein, making contacts with Ile56 and Tyr41/Val52/Ile77, 
respectively. These two Val residues function to anchor the P-loop to the four-helix bundle by 
hydrophobic interactions of the aliphatic side chains.   
 
Comparison between unphospho-, phospho-, and Asp-substituted CPI-17 structures 
Comparison of P-T38-CPI-17 structure with that in the unphospho-form (U-CPI-17) 
and D38-form (Ohki, et al, 2003) reveals global conformational change in response to 
phosphorylation (Figure 3) (Table S2). The most remarkable difference is the position of the 
key residue, Thr38, whose side chain comes out of a cavity between A and B helices upon 
phosphorylation. When structures are superimposed using the A/D helix pair for alignment 
(Figure 3, bottom), the phosphorylation at Thr38 is seen to trigger a swinging motion of the 
P-loop around the A-helix, resulting in 8.1 Å movement of residue 38. The swing of the 
P-loop is coupled with a right-handed rotation of A-helix by 29 degrees, along with a 
complementary rotation of the D-helix. These rotations expose new surfaces of both helices 
that become available for binding to myosin phosphatase.  Similar to U-CPI-17, the A/D 
helix-pair in P-T38-CPI-17 is stabilized by hydrophobic residues as shown in Figure 3. In 
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concert with motion of the A-helix, the B/C helix-pair becomes close to the A/D helix-pair. 
This aligns the four helices into an anti-parallel bundle (Table S3).  The average distance 
between the four helices becomes 15 % shorter (Table S3), and the compaction of the 
structure causes the overall surface area of the protein to be reduced from 7,221 to 6,374 Å2. 
Substitution of T38 to Asp results in the P-loop becoming exposed to solvent, consistent with 
changes in P-form.  However, the re-alignment of four helices is not evident in the D38 
protein relative to the U-CPI-17, and the overall structure remains V-shape (Figure 3, center). 
 
Formation of hydrophobic core 
The phosphorylation-induced compression of the four helices gathers Tyr41 in the 
P-loop, Leu46/Val52 in A-helix, and Ile77/Leu80/Leu81 in B-helix into a stable hydrophobic 
core (Figure 4A). For example, the distance between Val 52 and Ile77 Cα atoms shortens 
from 19.0 to 6.4 Å. Such hydrophobic clustering likely functions to stabilize the 
anti-parallel-aligned four-helix bundle of P-CPI-17. This stabilization reflects in higher 
heteronuclear NOE value of P-T38-CPI-17, compared with U- and D38-CPI-17 
(Supplementary Figure S3).  We assayed thermal stabilities of U-and P-T38-CPI-17, and 
indeed, phosphorylation increased the mean melting temperature T
m
 from 59 °C (U-CPI-17) 
to 64 °C (P-T38-CPI-17), showing an effect on the thermodynamic stability of the protein.  
We attribute this change to the hydrophobic core in P-T38-CPI-17 (Figure 4B).  The 
hydrophobic core is not well-defined in the D38-CPI-17 structure (Figure 4A, middle). 
Consistent with this observation, we found the thermal stability of D38-CPI-17 was lower 
(T
m
 = 54 °C), compared to P-T38-CPI-17 (Figure 4B).  Overall, the structure and thermal 
stability are consistent with the idea that phosphorylation but not mutation to an acidic 
residue triggers condensation of the protein into a rigid structure, with a surface topography 
distinctly different from the unphosphorylated protein.   
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The hydrophobic core of P-T38-CPI-17 
We examined effects of mutation of residues in the hydrophobic core on the 
inhibition of purified myosin phosphatase, using wild type CPI-17 and Y41A, W55A, 
D73A/E74A, and I77A/L80A/L81A mutants. All these recombinant CPI-17, were equally 
phosphorylated by purified PKC, suggesting that the mutations do not impair reaction with 
Thr38 (Table S4). However, the phosphorylated mutant CPI-17 showed different inhibitory 
potency (Figure 5A). Mutation at either Trp55 or Asp73/Glu74 caused moderate reduction in 
inhibitory potency, and the triple mutation of Ile77/Leu80/Leu81 showed greatly reduced 
potency, to an IC50 of around 100 nM. Our previous data showed that an Ala-mutation at 
Tyr41 (Y41A) eliminated the inhibitory activity of CPI-17 (Hayashi, et al, 2001). Thermal 
stability of the Y41A protein (Tm = 56 °C) was lower than that of wild type (Figure 4B, 
cross). We concluded that the hydrophobic clustering of Y41 and Ile77/Leu80/Leu81 was 
required for CPI-17 to act as an inhibitor for myosin phosphatase. The function of CPI-17 
mutated in the hydrophobic core was examined using beta-escin-permeabilized vas deferens 
smooth muscle tissues (Figure 5B).  Because CPI-17 is present at only negligible levels in 
vas deferens smooth muscle, phorbol ester (PDBu, a PKC activator) stimulation does not 
induce force production at limiting Ca2+ concentrations (Figure 5B, arrowhead) (Woodsome, 
et al, 2001).  Doping of recombinant U-CPI-17 into a permeabilized vas deferens smooth 
muscle strip restored PDBu-induced force production at clamped Ca2+ concentration, 
suggesting that PKC induced the phosphorylation of CPI-17 causing inhibition of the 
endogenous myosin phosphatase in the strip (Figure 5B, double arrowhead). The 
triple-mutant CPI-17, I77A/L80A/L81A or Y41A (Figure 5B), did not induce PKC-mediated 
smooth muscle contraction, suggesting that the formation of hydrophobic core is necessary 
for CPI-17 to inhibit myosin phosphatase in tissues. On the other hand, CPI-17 mutants 
D73A/E74A and W55A supported PDBu-induced force production. The maximum extent 
and the rate of force development were slightly lower with these mutant proteins, compared 
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with wild type -17. We note that D73, E74 and W55 are conserved among CPI-17 from 
various species, so changes in these residues have not survived probably because of the 
changes in properties. .  
 
Modeling of the interaction between P-T38-CPI-17 and myosin phosphatase  
The phospho-pivot computer modeling method was used to examine hypothetical 
docking of P-T38-CPI-17 with myosin phosphatase (Eto, et al, 2004; Matsuzawa, et al, 
2005a; Matsuzawa, et al, 2005b).  The phosphate group of P-T38-CPI-17 was set into the 
active site of PP1δ•MYPT1(1-299) complex (Terrak, et al, 2004), and 186,624 in-silico 
complexes were generated by rotating P-T38-CPI-17 around the phosphorus atom as a pivot. 
Each model complex was scored based on only atomic distances between two proteins.  The 
modeling yields one converged structure of P-CPI-17 on myosin phosphatase (Figure 6A). In 
this complex, the P-loop fits in the active site groove of PP1, from the cavity of 
ankyrin-repeat domain toward the N-terminal alpha-helical segment of MYPT1 (Terrak, et al, 
2004). This model suggests that four Arg side chains in P-loop, Arg 33, 36, 43, and 44, are 
involved in the interaction with myosin phosphatase, in addition to phospho-Thr38. This is 
consistent to our previous results that an Ala mutation of CPI-17 at Arg 43 and Arg 44 
impairs the inhibitory potency over 40 fold (Hayashi, et al, 2001).  Interestingly, this model 
positions Asp5 on N-terminal segment of MYPT1 in close proximity to Arg44 of 
P-T38-CPI-17 (Figure 6A).  Experimental testing of this model using immobilized peptides 
corresponding to MYPT1 segments (1-19) and (24-41) showed weak binding of 
P-T38-CPI-17 to MYPT1(1-19), but not to MYPT1(24-41) (Figure 6B). Thus, the N-terminal 
segment of MYPT1 (1-19) is possibly involved in the interaction with P-CPI-17.   
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DISCUSSION 
From comparison of the structures of the inactive U-CPI-17 and the active 
P-T38-CPI-17 we identify a conformational transition upon phosphorylation of CPI-17 at 
Thr38.  The phosphorylation induces a swing of the P-loop and a formation of the 
hydrophobic core to lock and stabilize a condensed active conformation of P-T38-CPI-17. 
We conclude that this swing-and-lock mechanism of CPI-17 is responsible for potent and 
specific inhibition of myosin phosphatase to switch phosphorylation levels of myosin and 
merlin in response to G-protein activation. All PP1 specific inhibitor proteins are regulated 
by phosphorylation, and five of them are in the CPI-17 family, based on the similarity of the 
sequences including residues in the hydrophobic core identified here by NMR , so these 
results should apply to other CPI-17 family members. On the other hand, phosphorylation of 
another class of PP1 inhibitors, inhibitor-1 and DARPP-32, apparently only induces a minor 
conformational change in the molecule, despite over 1000-fold increase in the inhibitory 
potency (Endo, et al, 1996; Neyroz, et al, 1993).  The phosphorylation-induced 
conformational switch seems to be a unique feature in the CPI-17 family of proteins. 
 
Asp- or Glu-substitution of Ser or Thr is often used for mimicking phosphorylation 
of proteins.  One example is the activation loop of protein kinases. Phosphorylation of 
protein kinases in the activation loop is required for full activity, and it can be mimicked by 
substitution with Asp or Glu (Zhang, et al, 1995).  The phosphate group in the activation 
loop of kinases directly forms salt bridges with Arg residues in N-terminal domain 
(Canagarajah, et al, 1997; Johnson, et al, 1996) and the effectiveness of Glu or Asp suggests 
these residues can form salt bridges with the same Arg. In contrast the phosphate of 
P-T38-CPI-17 is exposed to solvent and interacts instead with the active site of PP1 in 
myosin phosphatase.. Asp-substitution at Thr38 induces a swing of the P-loop, but not the 
same re-alignment of helices or formation of the hydrophobic core in the protein as is formed 
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when T38 is phosphorylated (Ohki, et al, 2003).  The failure of hydrophobic clustering in 
D38-CPI-17 is evidenced by lower thermal stability. Without the hydrophobic core there is a 
100-fold lower inhibitory potency of D38-CPI-17 compared to P-T38-CPI-17.  Thus, the 
negative charge of a carboxyl group is insufficient for completion of the conformational 
switching in CPI-17. This gives an example of where an acidic side chain is not 
phosphomimetic, offering a note of caution to the common practice of using properties of 
mutated proteins to make conclusions about effects of phosphorylation. 
 
Currently, about 150 protein structures with phospho-Thr are listed in PDB database.  
In most cases, the phosphate group is directly tethered to other residues in the same protein 
via salt bridges and/or hydrogen bonds. In this way the phosphate drives formation of a new 
protein conformation that is stabilized by these intramolecular interactions, as seen in 
glycogen phosphorylase-a and protein kinases (Johnson, et al, 1996; Sprang, et al, 1988).  
Another example is the NMR structure of a 44-residue P-Thr peptide mimicking the 
forkhead-associated (FHA) domain of human Ki67 protein in the complex with its receptor, 
the human nucleolar protein hNIHK, where the phosphate functions as a ligand (Byeon, et al, 
2005). Our studies reveal a different mechanism of phosphorylation-induced conformational 
change. The phospho conformation of the CPI-17 P-loop is stabilized without a hydrogen 
bond or salt bridge to the phosphate group from other residues in the protein.  Based on 
heteronuclear NOE data, the P-loop of unphosphorylated CPI-17 is highly flexible and this 
presumably exposes Thr38 to kinases, such as PKC and ROCK. Upon the phosphorylation of 
T38 the side chains of neighboring V37, V39 and Y41 anchor the P-loop to the hydrophobic 
core formed between the helices that restrains the overall solution structure.  The rigid 
structure of phosphorylated P-loop is likely critical for the potent inhibition of the 
phosphatase by positioning the phosphate relative to other residues in CPI-17 that form 
contacts with MYPT1 and PP1. When the hydrophobic core of P-T38-CPI-17 is perturbed by 
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Ala-substitution of Tyr41, the P-Thr38 residue is readily dephosphorylated by myosin 
phosphatase (Hayashi, et al, 2001). We propose that the rigidity of the structure due to the 
hydrophobic core is key to preventing hydrolysis of the P-T38, making P-T38-CPI-17 an 
inhibitor instead of a substrate. Thus, the swing-and-lock mechanism of CPI-17 activation 
restricts flexibility of the P-loop and protects P-Thr38 from being hydrolyzed at the active 
site of myosin phosphatase. Interestingly, P-T38 is hydrolyzed by other PP1 holoenzymes, 
such as glycogen phosphatase (a heterodimer of PP1 plus GM subunit), so phospho-CPI-17 
is both a substrate and an inhibitor, depending on the form of PP1 it encounters. 
Previously, phospho-pivot modeling with D38-CPI-17 (PDB: 1J2N) and monomeric 
PP1 alpha isoform catalytic subunit (1IT6) predicted critical roles for residues at the active 
site of PP1δ, namely D137, D193, R220, Y271, and E274  Indeed, these residues are 
necessary for the binding of PP1 δ with P-T38-CPI-17 in an in vitro assay (Matsuzawa, et al, 
2005a).These same residues at the PP1 active site seem to be involved in the model of the 
P-T38-CPI-17•PP1δ•MYPT1(1-299) complex.  However, the best fitting model was 
obtained when the pivot phosphorus atom was set at a position 0.5 Å away from the active 
site. Thus, the phosphate group is not in an optimum position for hydrolysis in this model. 
We speculate that weak interactions of the MYPT1 subunit with P-T38-CPI-17, perhaps 
involving the MYPT1 N-terminal (1-19) segment, displaces phospho-Thr38 from being in an 
optimum position at the PP1 active site for dephosphorylation. Some involvement of MYPT1 
seems to be needed to account for the inhibitor vs. substrate reaction of P-T38-CPI-17 with 
different PP1 holoenzymes.  
 
It is noteworthy that the phospho-pivot model positions the unstructured N-terminal 
tail of CPI-17 near the MYPT1 ankyrn repeat domain. Other CPI-17 family members, PHI-1 
and KEPI, also inhibit myosin phosphatase, but with different potencies. The IC50 for PHI-1 
(50 nM) is 50-fold higher than that for CPI-17, whereas KEPI inhibits myosin phosphatase 
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with IC50 of 0.1 nM (Erdodi, et al, 2003; Eto, et al, 1999). It is possible that the N-terminal 
tail of the different CPI-17 family members functions as a sensor for different regulatory 
subunits of PP1,  This gives us a future direction for studying functional diversity in the 
CPI-17 family. Despite a focus on the MYPT1 N terminal domain we cannot completely rule 
out involvement of the MYPT1 C-terminal domain and/or the M21 subunit in specific 
recognition of P-CPI-17.  Other PP1 inhibitor proteins are known to contact both PP1 
catalytic and regulatory subunits to form trimeric complexes that account for their selective 
inhibition of PP1 in different contexts. One example is inhibitor-1 binding to GADD-34 that 
is bound to PP1, and other examples are inhibitor-2 binding to either neurabin or KPI-2 that 
both bind PP1 at independent sites. (Connor, et al, 2001; Terry-Lorenzo, et al, 2002; Wang, et 
al, 2002). Inhibitor-2 also binds to PP1 that is engaged with an VxF motif in Nek2A, forming 
a heterotrimer with PP1 as the bridging protein (Eto, 2002 and Li 2007) Direct contact 
between regulatory subunits and PP1 inhibitor proteins is an attractive idea to provide 
signaling specificity for controlling individual PP1 complexes. The structure of an activated 
PP1 inhibitor gives general insight into phosphorylation-dependent conformational changes 
and regulation of cellular PP1, and opens a door to understanding mechanisms of signaling 
crosstalk between kinases and phosphatases.  
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METHODS 
Proteins:  The cDNA of CPI-17 was cloned from pig aorta smooth muscle library.  
Recombinant CPI-17 (22-120) for NMR was prepared using pET30 bacterial expression 
vector with the minimal medium containing 15N-ammnonium chloride and/or 13C-glucose as 
the sole source of nitrogen and/or carbon. This method yields the uniformly stable-isotope 
labeled (> 95 %) sample for NMR spectroscopy (Ohki, et al, 2001; Ohki, et al, 2003). CPI-17 
proteins for other assays are expressed as full-length versions with N-terminal His6- and 
S-tag™ sequences (Eto, et al, 2003). Phosphorylation of the protein was performed with an 
active fragment of PKC.  The active fragment of PKC was extracted from human red cells 
with hypotonic buffer and purified by ammonium sulfate precipitation, and sequencial 
column chromatographies using DEAE-Sepharose, Phenyl-Sepharose, Q-Sepharose and 
Protamine-agarose. Stoichiometric phosphorylation of CPI-17 was verified by urea-PAGE 
analysis (Figure S1), as described previously (Eto, et al, 2003).  Anti-P-T38-CPI-17 IgY 
was prepared using synthetic phospho-peptide as an antigen and purified by affinity 
chromatography, as described previously (Kitazawa, et al. 2000) (Aves Lab, Tigard OR).   
 
NMR structure determination:  All NMR data for ~1 mM P-T38-CPI-17 (in 50 mM 
phosphate buffer pH 6.8, 100 mM KCl, 1 mM DTT, and 0.02 % NaN3) were recorded on a 
Varian INOVA750 spectrometer. The sample temperature was kept at 25.0 oC. A set of two- 
and three-dimensional NMR data was obtained for resonance assignments (Bax, et al, 1992).  
Homonuclear 2D-NOESY, 15N-edited NOESY, and 13C-edited NOESY with mixing time of 
100 msec were recorded to collect distance information.  To obtain the information about 
hydrogen bonding, amide proton H-D exchange was monitored by 1H-15N HSQC. 
2D-HMQC-J spectra were also recorded to obtain dihedral angle constraints. All NMR data 
were processed using nmrPipe/nmrDraw (Delaglio, et al, 1995) and were analyzed with PIPP 
(Garrett, 1991).  Structure calculation was carried out using X-PLOR version 3.851 
  
16 
(Brunger, et al, 1998; Kleywegt, et al, 1998). Quality of each coordinate was examined by 
using AQUA/procheck-NMR (Laskowski, et al, 1996).  The Ramachandran plot analysis of 
the final structures showed that 1.7 ± 1.1% of non-glycine and non-proline residues were in 
the disallowed regions.   
 
Structural analysis: All structural images were drawn with MOLMOL (Koradi, et al, 1996), 
Molscript (Kraulis, 1991), and Raster3D (Merrit, et al, 1997). Vector geometry mapping and 
calculations of surface potential and area were done using an algorithm of Yap, et al. (Yap, et 
al, 2002) and PyMol Molecular Graphic System (http://www.pymol.org), respectively.  The 
rotation angle of A-helix was estimated from mean value of differences on Calpha-Cbeta 
angle of each residue.   
 
Phospho-pivot modeling: An in silico model of the ternary complex, P-T38-CPI-17 / PP1 
delta / MYPT1(1-299) was obtained using the phospho-pivot modeling method, as described 
previously (Matsuzawa, et al, 2005a; Matsuzawa, et al, 2005b). Structural data of 
P-T38-CPI-17 (present study) and the myosin phosphatase complex of MYPT1(1-299) and 
PP1 delta (Terrak, et al, 2004) were used for the modeling. The best result was obtained 
when the phosphate group of P-CPI-17 was placed at a point 0.5 Å-away from the putative 
phosphorus position.  The atomic distance violation was set with the threshold of 3.5 Å 
(Ca-Ca), or 2.0 Å (N-O, N-N, O-O). Models without distance violation between main chain 
atoms, identified as 68 out of 186,624 models, were subjected to an energy minimization 
process with permitted of structural adjustments on both molecules, using AMBER force 
field on SYBYL/BIOPOLYMER (Tripos Inc.).  In this modeling atoms within 8 Å of 
CPI-17 were used for the energy calculation.  The results of energy minimization were 
shown in Table S5.  The orientation of P-CPI-17 against MYPT1•PP1 complex is the same 
in 4 of the best 5 models. Both electrostatic and hydrogen-bonding energy values dominantly 
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contribute to the total binding force.  The best model (shown in Figure 6A) includes 15 
atomic violations.   
 
Assays: CD spectrum measurements were performed on a JASCO 720 spectropolarimeter at 
various temperatures (20 – 95 °C) with 20 µM U- and H6S-P-T38-CPI-17 full-length proteins 
in phosphate-buffered saline. Thermal stability of CPI-17 was assessed via the melting 
temperature (T
m
 ) from the plot of molar ellipticity at 222 nm against the temperature.  
Other assays were carried out at 20 °C.  The H6S-tag does not affect the CD spectrum (data 
not shown).  The inhibitory potency of CPI-17 proteins was measured using myosin 
phosphatase purified from pig aorta smooth muscle with 0.5 µM 32P-labeled phospho-myosin 
light chain as a substrate, at 20 °C (Eto, et al, 2003).  The Ca2+ sensitizing effect of CPI-17 
protein was examined at 20 °C in vas deferens smooth muscle strips permeabilized with 
beta-escin (Masuo, et al, 1994).  This tissue preparation s depleted to a minimum amount of 
endogenous CPI-17, but retains other regulatory proteins, such as myosin phosphatase, PKC 
and ROCK (Woodsome, et al, 2001).  Binding assay of P-CPI-17 was performed with 
synthetic segments of MYPT1 (1-19) and (24-41) (GenScript, Piscataway, NJ).  
MYPT1(1-19) and (24-41) peptides were immobilized onto Sulfo-link beads (Pierce) via a 
C-terminal Cys residue added for cross-linking, and then excess reactive groups on the beads 
were quenched with 50 mM L-Cys.  Blank beads for controls were treated with 50 mM 
L-Cys without peptide conjugation. H6S-P-T38-CPI-17 (0.1 µM) was mixed for 30 min at 
23 °C, with 10 µL of slurry in 150 µL of 50 mM MOPS-NaOH, pH 7.0 including 0.1 M 
NaCl, 1 mM EGTA, 0.1 % Tween 20, 5 % glycerol, 0.4 mM Pefabloc™, and 0.5 mM TCEP.  
The beads were washed with 100 µL of the binding buffer 3 times, and bound CPI-17 was 
detected by immunobloting with anti-CPI-17 using FluoroChemSP CCD imaging system 
(Alpha-Innotech).  Relative amount of bound CPI-17 was obtained from three independent 
experiments by quantifying the band intensity using AlphaEace FC imaging software.    
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Accession codes in Protein Data Bank and BioMagResBank 
 The atomic coordinates and the chemical shift table of P-T38-CPI-17(22-120) 
protein are deposited in the Protein Data Bank (2RLT) and BioMagResoBank (15428), 
respectively.   
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FIGURE LEGENDS 
Figure 1. Inhibitory domain of CPI-17 family. (A) Amino acid sequence of CPI-17 
family of PP1 inhibitor proteins.  Asterisk indicates Thr38, and arrows indicate Trp55, Ile77, 
Leu80, and Leu81. Boxes show regions in helices A to D. (B) 1H-15N HSQC spectrum of 
13C/15N-labeled P-CPI-17 (1 mM).  Red, gray and blue indicate amide resonances of P-, U-, 
and D38-CPI-17(22-120), respectively.  Resonance peaks of T38, V39 and V41 were 
connected by arrows, from U-form to P- or D38-form.   
 
Figure 2. Solution NMR structure of phospho-CPI-17(22-120).  (A) Stereo view 
of the backbone of 20 superimposed structures obtained by NMR analysis. Red indicates the 
region of α-helix. (B) Ribbon representation of an energy-minimized average structure. In 
the ribbon model, the flexible N-terminal 31 residues are not depicted. T38 and residues 
involved in hydrophobic clustering are drawn with ball-and-stick side chains labeled with 
residue numbers to facilitate identification, and the helices are labeled with upper case letters. 
(C) Space-filling representation with molecular surface potential, superimposed on backbone 
structure (green).  Red and blue on surface indicate regions of negative and positive charges, 
respectively. A side chain of P-T38 is drawn as ball-and-stick.   
 
Figure 3. Conformational transition of CPI-17 upon phosphorylation.  
U-CPI-17 (1J2M) (left) D38-CPI-17 (1J2N) (middle) and P-T38-CPI-17 (right) are displayed 
as ribbon structures.  Side chains of hydrophobic residues that tether Helix A to D are 
shown as ball-and-stick for emphasis.   
 
Figure 4. Formation of the hydrophobic core in P-CPI-17.  (A) Top, middle, and 
bottom panels represent the structures of U-, D38-, and P-T38-CPI-17, respectively.  
Hydrophobic side chains responsible for the condensed conformation are displayed as Corey, 
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Pauling and Koltun colored model.  (B) Thermal stability of CPI-17 proteins monitored by 
circular dichroism (CD). Vertical axis shows relative change of the molar ellipticity at 222 
nm at indicated temperature. CD spectrum was measured with 20 µM protein; P-T38-CPI-17 
(open circle), U-CPI-17 (closed circle), D38-CPI-17 (Rectangle), and P-T38-CPI-17 (Y41A) 
(cross), in 50 mM potassium phosphate buffer, pH 7.0.  Mean values from triplicate assays 
are shown.   
 
Figure 5. Effects of the mutation in the hydrophobic core on the inhibitory 
potency of CPI-17. (A) Inhibition of myosin phosphatase purified from pig aorta. The 
myosin phosphatase activity without inhibitor proteins was set as 100 %. Data are averaged 
from two independent assays done in duplicate.   (B) Force measurement of vas deferens 
smooth muscle strip. Panels represent the time-dependent force trace with U-CPI-17: wild 
type, D73A/E74A, I77A/L80A/L81A and W55A.  The rabbit vas deferens smooth muscle 
strips were permeabilized with beta-escin. The CPI-17 proteins were doped into the tissue 
after the addition of PDBu.  The extent of contraction in the presence of 1 µM Ca2+ is set as 
100 % value.  
 
Figure 6. Interaction of P-CPI-17 with PP1•MYPT1 complex.   (A) The 
coordinates of MYPT1(1-299)•PP1 complex (1S70) in Protein Data Bank were used for 
computer modeling of the complex. MYPT1 (yellow) and PP1 (cyan) are depicted in a 
surface model, and P-T38-CPI-17 is drawn as a ribbon structure.  The positive charge of 
MYPT1 Asp5 is shown as red, and the side chains of phospho-Thr38 and Arg43/44 in CPI-17 
are shown as sticks.  (B) Binding assay of P-T38-CPI-17 was performed with synthetic 
peptides corresponding to MYPT1 segments (1-19) and (24-41), immobilized on agarose 
beads.  Asp5 is indicated by arrowhead in the sequence.  Bound P-T38-CPI-17 was 
quantified by immunoblotting with anti-CPI-17 antibody (top).  Mean values from 3 
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independent experiments are represented as a bar graph.  Student’s t test was used to assess 
significance and * and ** indicate p > 0.15 and P < 0.03 respectively.  
 
